CN107759654A - The application of Radix Astragali thuja acid and its derivative in antithrombotic reagent is prepared - Google Patents
The application of Radix Astragali thuja acid and its derivative in antithrombotic reagent is prepared Download PDFInfo
- Publication number
- CN107759654A CN107759654A CN201711019204.XA CN201711019204A CN107759654A CN 107759654 A CN107759654 A CN 107759654A CN 201711019204 A CN201711019204 A CN 201711019204A CN 107759654 A CN107759654 A CN 107759654A
- Authority
- CN
- China
- Prior art keywords
- radix astragali
- thuja acid
- derivatives
- group
- astragaloside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
Abstract
The present invention relates to pharmaceutical technology field.Purpose is to provide application of the Radix Astragali thuja acid in antithrombotic reagent is prepared.The invention discloses application of the orientation derivative Radix Astragali thuja acid of Astragaloside IV in antithrombotic reagent is prepared.Radix Astragali thuja acid can be obviously prolonged the clotting time of blood, the formation of effective pre- preventing thrombosis.Pharmacological evaluation shows that Radix Astragali thuja acid is relatively reliable to the prevention effect of thrombus compared with Astragaloside IV, effective, and the druggability of Radix Astragali thuja acid is also remarkably reinforced compared with Astragaloside IV.Simultaneously, Radix Astragali thuja acid is processed to obtain by native compound Astragaloside IV, its processing method is simple, high income, stable in physicochemical property, and condition of storage is simple, preparation is convenient, a variety of formulations can be made, be easy to take, Radix Astragali thuja acid is developed as a kind of antithrombotic reagent, have a extensive future, there is huge market potential and social value.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to Radix Astragali thuja acid and its derivative are in antithrombotic reagent is prepared
Using.
Background technology
Thrombus be blood constituent in the endovascular abnormal aggregation of body local, with the continuous improvement of people's living standards,
The incidence of disease of thrombotic diseases increases year by year.The reason for thrombosis, includes the heart, blood vessel internal membrane damage, hemodynamic change and blood borne
Matter changes, and its forming process is by inherent cause and environmental factor interaction, interactional multifactor change procedure.Body
Normal coagulation, depend on complete wall structures and function, effective platelet quality and quantity, normal blood plasma
Coagulation factor activity.Thrombus is more readily formed in the elderly, because with the growth at people's age, internal Fibrinolytic System
Gradually reduce, blood coagulation and anticoagulant functions disequilibrium in blood and there is abnormal blood coagulation, i.e. thrombus.
The incidences of disease of thrombotic diseases, fatal rate and disability rate are very high.Arterial thrombosis causes more than 90%
The main reason for myocardial infarction, 80% cerebral apoplexy, it is the cause of death that first place is ranked in developed country；VTE is sick to be also
The cause of death of the 3rd is ranked in developed country.It is one of the disease for seriously endangering human health, and countries in the world medicine
The focus of scholar's research.With the understanding intensification to thrombosis mechanism, for preventing and treating the medicine of thrombus also continuous
Research and development, are clinically broadly divided into 3 classes, the medicine of antiplatelet medicine, anticoagulant medicine and thrombus, seek one at present
Kind is effective, reliable antithrombotic reagent is still significant.
Radix Astragali thuja acid is to carry out chemical improvement to Astragaloside IV molecule, optionally by glucosyl group in Astragaloside IV molecule
On C6The product for locating methylol selective paraffin oxidation to obtain after carboxyl.Astragaloside IV be Chinese herbal medicine astragalus main active it
One, and《Chinese Pharmacopoeia》The qualitative and quantitative index composition of middle plurality of Chinese compound preparation, having improves cardio-pulmonary function, enhancing machine
The multiple pharmacological effects such as body immunity.And Radix Astragali thuja acid is remarkably reinforced compared with Astragaloside IV water solubility, can be opened as single preparations of ephedrine
The exploitation of hair, especially its salt particularly suitable as water-soluble dosage forms such as parenteral solution, big transfusions.
The content of the invention
It is an object of the invention to provide the application of Radix Astragali thuja acid and its derivative in antithrombotic reagent is prepared.
For achieving the above object, the technical solution adopted in the present invention is：The medicine of Radix Astragali thuja acid or derivatives thereof
New application, it is characterised in that：Radix Astragali thuja acid or derivatives thereof is used to prepare antithrombotic reagent, the Radix Astragali thuja acid or derivatives thereof
Structural formula be：
Wherein, R is one kind in hydrogen ion or ionizable metal salt or saturated alkyl or amino.
Preferably：Described antithrombotic reagent is anticoagulant medicine.
Preferably：Described antithrombotic is anti-phlebothrombosis.
Preferably：Also include pharmaceutically acceptable carrier, assistant agent or medium in described medicine.
Preferably：Described saturated alkyl is C1~C5Side chain or branched alkyl.
Preferably：The derivative is one kind in Radix Astragali thuja acid sodium, Radix Astragali thuja acid methyl esters, astragalin acid amides.
Tablet, capsule or injection is made in above-mentioned medicine.
The invention discloses application of the orientation derivative Radix Astragali thuja acid of Astragaloside IV in antithrombotic reagent is prepared.The Radix Astragali
Thuja acid can be obviously prolonged the clotting time of blood, the formation of effective pre- preventing thrombosis.Pharmacological experiment shows, Radix Astragali thuja acid for
The thrombus of Ponatinib and arachidonic acid-induction has good prevention effect, and prevention effect more may be used compared with Astragaloside IV
Lean on, effectively, and the druggability of Radix Astragali thuja acid is also remarkably reinforced compared with Astragaloside IV.Meanwhile Radix Astragali thuja acid is yellow by native compound
Stilbene first glycosides processes what is obtained, and its processing method is simple, high income, and stable in physicochemical property, condition of storage is simple, and preparation is convenient, energy
A variety of formulations are enough made, are easy to take, Radix Astragali thuja acid is developed as a kind of antithrombotic reagent, is had a extensive future, and is had huge
Market potential and social value.
Brief description of the drawings
Fig. 1 is that each experimental group induces the thrombosed heart red blood cell staining power quantitative assessment of zebra fish to Ponatinib
(n=10) compared with model control group, * * * Ρ<0.001；
Fig. 2 is that each experimental group induces the thrombosed prevention effect of zebra fish to Ponatinib, with model control group ratio
Compared with * * * Ρ<0.001；
Fig. 3 is that each experimental group induces the thrombosed heart red blood cell staining power quantitative assessment of zebra fish to Ponatinib
Typical picture；
Fig. 4 is that each experimental group induces the thrombosed prevention effect typical picture of zebra fish to Ponatinib；
Fig. 5 is each experimental group to arachidonic acid-induction zebra fish thrombosis qualitative evaluation typical picture；
Fig. 6 is that each experimental group is quantitatively commented the thrombosed heart red blood cell staining power of arachidonic acid-induction zebra fish
Valency typical picture；
Fig. 7 is that each experimental group is quantitatively commented the thrombosed heart red blood cell staining power of arachidonic acid-induction zebra fish
Valency (n=10) is compared with model control group, * * * Ρ<0.001；
Fig. 8 be Fig. 2 be each experimental group to the thrombosed prevention effect of arachidonic acid-induction zebra fish, with model comparison
Group compares, * * * Ρ<0.001.
Embodiment
Technical scheme disclosed by the invention is further described with reference to embodiment 1-10 and accompanying drawing.But these
Specific experiment and accompanying drawing are exemplary, it is impossible to treat them as limitation of the present invention.
Embodiment one：Anti- rat vein thrombosis
Material prepares：Animal SD rats 40, male and female half and half, 190~210g of body weight.
Experimental method：SD rats are randomly divided into four groups, every group 10, are respectively set to high, medium and low dosage group and blank
Control group.Wherein, the dosage of high dose group is 10mg/kg, middle dose group 5mg/kg, low dose group 2.5mg/kg, empty
White control group is not administered.
Radix Astragali thuja acid is mixed with carboxymethyl cellulose, is administered once to each group rat oral gavage, blank control group same volume
Carboxymethyl cellulose gavage.After 30min is administered, the capillary glass tube for being 1mm with internal diameter insertion mouse angular vein clump takes blood, extremely
Capillary column reaches 5cm, is fractureed capillary every 30s, checks for blood clotting silk occur, calculates capillary blood sampling tube to there is blood clotting
Silk time, as clotting time.
Experimental result：It is shown in Table 1.
Table 1 is thrombotic on rat vein to influence (X soil S)
| Experiment packet | Size of animal (only) | Clotting time (second) |
| High (10mg/kg) dosage group | 10 | 90.00 native 12.34** |
| In (5mg/kg) dosage group | 10 | 80.00 native 18.33* |
| Low (2.5mg/kg) dosage group | 10 | 60.00 soil 21.12 |
| Blank control group | 10 | 50.00 soil 19.34 |
Note：Compared with blank control group (one-way analysis of variance), * Ρ<0..05, * * Ρ<0.01.
It can be seen from table 1：Radix Astragali thuja acid can extend the clotting time, and the wherein clotting time of low dose group is compared with blank control
Group slightly extends, but DeGrain；There is significant difference in high dose group and middle dose group, can be obvious with blank control group
Extend the clotting time.
Embodiment two：The prevention effect formed to Ponatinib inducing thrombosis
The prevention effect that evaluation Radix Astragali thuja acid sodium is formed to Ponatinib inducing thrombosis, method are as follows：
1), material prepares：Selection is using the progress of natural paired cross modes of reproduction, age as the after fertilization wild type AB of 5 days
Strain zebra fish, totally 270 tail, is randomly divided into nine groups, every group of 30 tails；Radix Astragali thuja acid sodium powder end is prepared with dimethyl sulfoxide (DMSO)
Mother liquor into 250mg/ml is standby, 4 DEG C of storages.
2), experimental method：Nine groups of zebra fish are respectively set to Normal group, model control group, positive controls, right
According to test sample group, low dose group, middle low dose group, middle dose group, middle high dose group and high dose group.Wherein, Normal group
It is not administered；Thrombus model is established in the processing of model control group Ponatinib；45 μ g/mL of positive controls aspirin (purchase
From Shanghai Jingchun Industrial Co., Ltd., the solution of normal concentration is configured to dimethyl sulfoxide (DMSO)) and Ponatinib be jointly processed by spot
Horse fish；Compare Astragaloside IV (solution that normal concentration is configured to the dimethyl sulfoxide (DMSO)) He Puna of test sample group with 50 μ g/mL
Zebra fish is jointly processed by for Buddhist nun；Each dosage group is from low to high respectively with 15.6,31.3,62.5,125 and 250 μ g/mL astragalin
Sour sodium and Ponatinib are jointly processed by zebra fish.
After 18h, dyed with dianisidine, 10 tails randomly selected from each group, disecting microscope (SZX7,
OLYMPUS, Japan) under shoot, with NIS-Elements DTMImage processing software carries out graphical analysis, and analytic statistics heart is red
Staining intensity of cells (S), Ponatinib is lured with the statistical significance evaluation " Radix Astragali thuja acid sodium " of heart red blood cell staining power
The thrombosis prevention effect led.Mean ± SE the expressions of statistical procedures result, the effect of " Radix Astragali thuja acid sodium " pre- preventing thrombosis
Calculation formula is as follows：
Evaluation result：It is shown in Table 2.
Table 2 induces Ponatinib the prevention effect of zebra fish thrombus model
Note：Positive control drug is aspirin；Compared with model control group, * * * Ρ<0.001.
Understand that model control group zebra fish heart red blood cell staining power (1018) is with compareing with reference to accompanying drawing 1~4 and table 2
Group (1748) compares P<0.001, the model is successfully established.Positive control drug has antithrombotic effect in 45 μ g/mL concentration.
And Astragaloside IV is in 50 μ g/mL, without the effect of antithrombotic, during actual dosing, the Radix Astragali of higher concentration
First glycosides has to zebra fish compared with strong stimulation, and 100 μ g/mL can cause 6.6% zebra fish dead.Therefore Astragaloside IV is in maximal tolerance dose
In the range of be difficult to produce effective prevention effect to thrombosis.In the five kinds of concentration used to Radix Astragali thuja acid sodium, 250 μ g/mL couple
The zebra fish thrombosis that Ponatinib induces has prevention effect.
Embodiment three：To the thrombotic prevention effect of arachidonic acid-induction
Radix Astragali thuja acid methyl esters is evaluated to the thrombotic prevention effect of arachidonic acid-induction, evaluation method：
1), material prepares：Selection is using the progress of natural paired cross modes of reproduction, age as 3 days melanin of after fertilization etc.
The position translucent Albino strains zebra fish of genic mutation type, totally 270 tail, is randomly divided into nine groups, every group of 30 tails；By astragalin
The mother liquor that sour methacrylate powder is configured to 100mg/mL with dmso solution is standby, and -20 DEG C are kept in dark place；
2), experimental method：Nine groups of zebra fish are respectively set to Normal group, model control group, positive controls, right
According to test sample group, low dose group, middle low dose group, middle dose group, middle high dose group and high dose group.Wherein, Normal group
It is not administered；The water-soluble arachidonic acid 1.5h that gives of model control group establishes thrombus model；Positive controls are with 25 μ g/mL Ah Si
It is water-soluble after woods (being purchased from Shanghai Jingchun Industrial Co., Ltd., the solution of normal concentration is configured to dimethyl sulfoxide (DMSO)) processing 3h
Give arachidonic acid and induce zebra fish thrombus model；It is (sub- with dimethyl with 100 μ g/mL Astragaloside IV to compare test sample group
Sulfone is configured to the solution of normal concentration) processing 3h after, it is water-soluble give arachidonic acid induce zebra fish thrombus model；Each dosage group
It is water-soluble to give peanut four after handling 3h with 6.25,12.5,25,50 and 100 μ g/mL Radix Astragali thuja acid methyl esters respectively from low to high
Olefin(e) acid induces zebra fish thrombus model.
After 1.5h, dyed with dianisidine, 10 tails randomly selected from each group, disecting microscope (SZX7,
OLYMPUS shooting and gathered data, qualitative evaluation zebra fish thrombosis, with NIS-Elements D3.10 high visions under)
Handle software and carry out graphical analysis, analytic statistics heart red blood cell staining power (S), and carry out analytic statistics, according to statistics
Evaluation " Radix Astragali thuja acid methyl esters " and " Astragaloside IV " are to the thrombotic prevention effect of zebra fish.Statistical procedures result is used
Mean ± SE represents that " Radix Astragali thuja acid methyl esters " and " Astragaloside IV " is calculated zebra fish thrombosis prevention effect with aspirin
Formula is as follows：
Evaluation result：It is shown in Table 3.
Prevention effect of the table 3 to arachidonic acid-induction zebra fish thrombus model
Note：Positive control drug is aspirin；Compared with model control group, * * * Ρ<0.001.
Understood with reference to the table 2 of accompanying drawing 5~8, model control group zebra fish heart red blood cell staining power (1397) and control group
(2305) P is compared<0.001, the model is successfully established.Positive control drug has antithrombotic effect in 25 μ g/mL concentration.And
Astragaloside IV is in 100 μ g/mL, without the effect of antithrombotic.In the five kinds of concentration used to Radix Astragali thuja acid methyl esters, 50
The zebra fish thrombosis induced under μ g/mL and 100 μ g/mL concentration conditions arachidonic acid has prevention effect.
Example IV：
The anti-rat vein thrombosis of astragalin acid amides is evaluated, method is as follows：
Material prepares：Animal SD rats 40, male and female half and half, 190~210g of body weight.
Experimental method：SD rats are randomly divided into four groups, every group 10, are respectively set to high, medium and low dosage group and blank
Control group.Wherein, the dosage of high dose group is 10mg/kg, middle dose group 5mg/kg, low dose group 2.5mg/kg, empty
White control group is not administered.
Astragalin acid amides is prepared with carboxymethyl cellulose, is administered once to each group rat oral gavage, blank control group is androgynous
Long-pending carboxymethyl cellulose gavage.After 30min is administered, the capillary glass tube for being 1mm with internal diameter insertion mouse angular vein clump takes blood,
5cm is reached to capillary column, is fractureed capillary every 30s, checks for blood clotting silk occur, calculates capillary blood sampling tube to there is blood
Solidifying silk time, as clotting time.
Experimental result：It is shown in Table 4.
The astragalin acid amides of table 4 is thrombotic on rat vein to influence (X soil S)
| Experiment packet | Size of animal (only) | Clotting time (second) |
| High (10mg/kg) dosage group | 10 | 93.00 native 12.52** |
| In (5mg/kg) dosage group | 10 | 82.00 native 12.28* |
| Low (2.5mg/kg) dosage group | 10 | 61.00 soil 19.21 |
| Blank control group | 10 | 50.00 soil 19.34 |
Note：Compared with blank control group (one-way analysis of variance), * Ρ<0..05, * * Ρ<0.01.
It can be seen from table 1：Astragalin acid amides can extend the clotting time, and the wherein clotting time of low dose group is compared with blank pair
Slightly extend according to group, but DeGrain；There is significant difference in high dose group and middle dose group, can be bright with blank control group
It is aobvious to extend the clotting time.
Embodiment five：
The preparation of antithrombotic tablet containing Radix Astragali thuja acid：
The Radix Astragali thuja acid that quality is 0.5g is well mixed with 10g pregelatinized starch, 0.3g sodium carboxymethylcellulose,
Granulation；0.05g superfine silica gel powder is added into particle, then by dry particl tabletting, is produced.
Embodiment six：
The preparation of antithrombotic tablet containing Radix Astragali thuja acid：
The Radix Astragali thuja acid that quality is 6g is well mixed with 100g lactose, 2g sodium carboxymethylcellulose, pelletized；To
0.4g talcum powder is added in grain, then by dry particl tabletting, is produced.
Embodiment seven：
The preparation of antithrombotic tablet containing Radix Astragali thuja acid：
By the Radix Astragali thuja acid and 440g dextrin, 4g 4% polyvinylpyrrolidone and 3g carboxymethyl that quality is 20g
Sodium starch is well mixed, granulation；1.4g magnesium stearate is added into particle, then by dry particl tabletting, is produced.
Embodiment eight：
The preparation of antithrombotic capsule containing Radix Astragali thuja acid methyl esters：
It is that 2g Radix Astragali thuja acid methyl esters is well mixed with 42g starch, 0.8g sodium carboxymethylcellulose by quality, pelletizes；
Gained particle is dried at a temperature of 55~70 DEG C, whole grain of sieving, is loaded capsule, is produced.
Embodiment nine：
The preparation of antithrombotic capsule containing Radix Astragali thuja acid：
It is that 30g Radixs Astragali thuja acid is well mixed with 550g starch, 4g Ac-Di-Sol by quality, Ran Houjia
Enter 50g70% alcohol granulation；Gained particle is dried at a temperature of 55~70 DEG C, whole grain of sieving, is loaded capsule, is produced.
Embodiment ten：
The preparation of antithrombotic injection containing Radix Astragali thuja acid sodium：
It is that 1g Radix Astragali thuja acids sodium is added in 120mL water for injection by quality, with 0.65 μm of filtering with microporous membrane, checks
It is filling after clarity is qualified, produce.
Claims (7)
- A kind of 1. new medicine use of Radix Astragali thuja acid or derivatives thereof, it is characterised in that：Radix Astragali thuja acid or derivatives thereof is used to make It is for the structural formula of antithrombotic reagent, the Radix Astragali thuja acid or derivatives thereof：Wherein, R is one kind in hydrogen ion or ionizable metal salt or saturated alkyl or amino.
- 2. the new medicine use of Radix Astragali thuja acid according to claim 1 or derivatives thereof, it is characterised in that：Described anti-blood Bolt medicine is anticoagulant medicine.
- 3. the new medicine use of Radix Astragali thuja acid according to claim 1 or derivatives thereof, it is characterised in that：Described anti-blood Bolt is anti-phlebothrombosis.
- 4. the new medicine use of Radix Astragali thuja acid according to claim 1 or derivatives thereof, it is characterised in that：The described Radix Astragali Thuja acid or derivatives thereof coordinates pharmaceutically acceptable carrier, assistant agent or medium.
- 5. the new medicine use of Radix Astragali thuja acid according to claim 1 or derivatives thereof, it is characterised in that：Described saturation Alkyl is C1~C5Side chain or branched alkyl.
- 6. the new medicine use of Radix Astragali thuja acid according to claim 1 or derivatives thereof, it is characterised in that：The derivative It is one kind in Radix Astragali thuja acid sodium, Radix Astragali thuja acid methyl esters, astragalin acid amides.
- 7. the new medicine use of the Radix Astragali thuja acid according to any one in claim 1-4 or derivatives thereof, its feature exists In：Described medicine is tablet, capsule or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711019204.XA CN107759654B (en) | 2017-10-27 | 2017-10-27 | Application of astragaloside and derivatives thereof in preparation of antithrombotic drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711019204.XA CN107759654B (en) | 2017-10-27 | 2017-10-27 | Application of astragaloside and derivatives thereof in preparation of antithrombotic drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107759654A true CN107759654A (en) | 2018-03-06 |
| CN107759654B CN107759654B (en) | 2020-02-21 |
Family
ID=61271638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711019204.XA Active CN107759654B (en) | 2017-10-27 | 2017-10-27 | Application of astragaloside and derivatives thereof in preparation of antithrombotic drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107759654B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111518156A (en) * | 2020-05-29 | 2020-08-11 | 中国科学院成都生物研究所 | One-step preparation method of astragaloside |
| CN115645418A (en) * | 2022-11-11 | 2023-01-31 | 中国医学科学院药用植物研究所 | Application of cycloastragenol and composition in preparation of anti-platelet and anti-thrombosis drugs |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1369289A (en) * | 2001-11-23 | 2002-09-18 | 曹柱 | Chinese medicine for treating cardiovascular and cerebrovascular diseases and its preparing process |
| CN1539464A (en) * | 2003-10-30 | 2004-10-27 | 军 解 | Capsule of Chinese traditional medicine for treating thrombus |
| CN104147032A (en) * | 2014-07-29 | 2014-11-19 | 广东众生药业股份有限公司 | Drug composition for preventing and treating related diseases of ischemic stroke as well as preparation method and applications thereof |
| CN106632572A (en) * | 2016-12-16 | 2017-05-10 | 中国科学院成都生物研究所 | Astragaloside derivative and preparation method and application thereof |
-
2017
- 2017-10-27 CN CN201711019204.XA patent/CN107759654B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1369289A (en) * | 2001-11-23 | 2002-09-18 | 曹柱 | Chinese medicine for treating cardiovascular and cerebrovascular diseases and its preparing process |
| CN1539464A (en) * | 2003-10-30 | 2004-10-27 | 军 解 | Capsule of Chinese traditional medicine for treating thrombus |
| CN104147032A (en) * | 2014-07-29 | 2014-11-19 | 广东众生药业股份有限公司 | Drug composition for preventing and treating related diseases of ischemic stroke as well as preparation method and applications thereof |
| CN106632572A (en) * | 2016-12-16 | 2017-05-10 | 中国科学院成都生物研究所 | Astragaloside derivative and preparation method and application thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111518156A (en) * | 2020-05-29 | 2020-08-11 | 中国科学院成都生物研究所 | One-step preparation method of astragaloside |
| CN111518156B (en) * | 2020-05-29 | 2021-07-27 | 中国科学院成都生物研究所 | One-step preparation method of astragaloside |
| CN115645418A (en) * | 2022-11-11 | 2023-01-31 | 中国医学科学院药用植物研究所 | Application of cycloastragenol and composition in preparation of anti-platelet and anti-thrombosis drugs |
| CN115645418B (en) * | 2022-11-11 | 2024-01-30 | 中国医学科学院药用植物研究所 | Application of cycloastragenol and composition in preparation of anti-platelet and antithrombotic drugs |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107759654B (en) | 2020-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104146976B (en) | Heavy-load valproic acid drug sustained release tablet and preparation method thereof | |
| CN107759654A (en) | The application of Radix Astragali thuja acid and its derivative in antithrombotic reagent is prepared | |
| CN105903021A (en) | Fullerene nano-material for preventing and/or treating aplastic anemia and use thereof | |
| Hall et al. | Human plasma and urine quinine levels following tablets, capsules, and intravenous infusion | |
| CN110559419A (en) | traditional Chinese medicine composition for preventing and conditioning hypertension and preparation method thereof | |
| Sarkar et al. | Evaluation of processed borax as antidote for aconite poisoning | |
| CN105362736A (en) | Medicine for treating chicken coccidiosis and preparation method of medicine | |
| CN101129972B (en) | Traditional Chinese medicine composition, preparation method and use of the same | |
| CN103372052B (en) | Traditional Chinese medicine compound preparation for treating leucoderma and preparation method thereof | |
| CN1981779B (en) | Xanthosine composition and its production method | |
| CN109985059A (en) | Dendrobium polysaccharide Reproductive Damage after preparing cancer chemotherapy restores the application in drug | |
| CN104606226B (en) | Anti-inflammation Chinese medicine suppository and preparation method thereof and quality control method | |
| CN105381024A (en) | Pharmaceutical composition for treating chicken coccidiosis and preparation method thereof | |
| CN105434358A (en) | Pharmaceutical composition containing taurine and application of pharmaceutical composition | |
| JP3861295B2 (en) | Blood flow improver | |
| CN110522764A (en) | Composition and application thereof containing derivatives of prostaglandins and inorganic salts | |
| CN105748427B (en) | A kind of Topiroxostat enteric coatel tablets and preparation method thereof | |
| CN108310125A (en) | The glad application in antithrombotic reagent in forefront | |
| CN100415226C (en) | Electrolyte replenisher for treating hypopotassaemia hypomagnesemia and its uses | |
| CN103172622B (en) | The active isomer of silybin bis-bias succinate | |
| CN103193768B (en) | The silybin bis-bias succinate isomer for the treatment of hepatopathy | |
| CN110339169A (en) | Coat nano vesicle preparations and its application of vitamin D and vitamin K | |
| CN110127642B (en) | Argon-containing compound, and preparation method and application thereof | |
| CN109771428A (en) | Celastrol combines application of the erastin in the drug for the treatment of non-small cell lung cancer | |
| CN100482245C (en) | Medicine composition contg. isatis root and scutellariae glucoside |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |